Substance Use Disorders at AAAP 37th Annual Meeting and Scientific Symposium

87 sessions on substance use disorders · November 12–15, 2026, Memphis, TN. Compare substance use disorders at other meetings →

Thursday, November 12

Friday, November 13

  • 09:00–10:40 · Symposium

    Symposium II - Neuromodulation to Treat Addictions: What’s Available and What’s in the Pipeline

    Manish Jha · Kathleen Brady · Hamed Ekhtiari · Gregory Sahlem · Brian Mickey

    Examines current and emerging neuromodulation approaches such as rTMS and focused ultrasound for treating substance use disorders, including personalization and response monitoring.

    Neuromodulation (ECT, TMS) · Drug Pipeline & Clinical Trials

  • 15:30–17:00 · Oral abstract

    Long-Acting Injectable Antipsychotics in Serious Mental Illness with Co-Occurring Substance Use: A Retrospective Cohort Study

    Kathryn Renard

    Cohort study of long-acting injectable antipsychotic use in patients with serious mental illness and substance use.

    Long-Acting Injectables · Serious Mental Illness

  • 15:30–17:00 · Oral abstract

    Nearcasting the Overdose Crisis: Key Insights from US Drug Dynamics

    Joseph Friedman

    Presents near-real-time modeling of US overdose and drug supply trends.

    Opioid Use Disorder

  • 15:30–17:00 · Oral abstract

    Prize-based versus Voucher-based Contingency Management protocols for Stimulant-Opioid Co-Use: A Network Meta-Analysis

    Henrique Oliva

    Network meta-analysis comparing prize- and voucher-based contingency management for stimulant-opioid co-use.

    Opioid Use Disorder · Psychotherapy

  • 15:30–17:00 · Oral abstract

    Serious Mental Illness and Outcomes in Inpatient Detoxification and Rehabilitation: A Retrospective Cohort Study

    Sean Lynch

    Cohort study of how serious mental illness affects inpatient detoxification and rehabilitation outcomes.

    Serious Mental Illness

  • 15:30–17:00 · Oral abstract

    Short-Term Clinical Outcomes in Early Psychosis with and without Recent Substance Use: The Role of Urine Drug Screening and Antipsychotics in an Urban Youth Cohort

    Chaden Noureddine

    Looks at short-term outcomes in youth with early psychosis by recent substance use, urine drug screening and antipsychotic use.

    Child & Adolescent · Schizophrenia & Psychosis

  • 15:30–17:00 · Oral abstract

    Substance Use and Outcomes following Intramuscular Antipsychotic Treatment for Acute Pediatric Agitation: A Retrospective Cohort Study

    Angelo Chaia

    Retrospective study of outcomes after intramuscular antipsychotics for pediatric agitation, by substance use status.

    Antipsychotic Prescribing · Child & Adolescent · Emergency & Acute Psychiatry

  • 15:30–17:00 · Oral abstract

    Using Big Data to Monitor Substance-Related Morbidity in Hispanic/Latine Americans: A National Analysis, 2019–2023

    Brian Tirado

    National data analysis of substance-related morbidity among Hispanic/Latine Americans.

    Diverse & Underserved Populations

  • 15:30–17:00 · Oral abstract

    Absolute and Relative Responses of Pharmacological Treatments for Gambling Disorder: A Systematic Review and Meta-Analysis

    Rory Pfund

    Meta-analysis of absolute and relative treatment responses to medications for gambling disorder.

    Drug Pipeline & Clinical Trials

  • 15:30–17:00 · Oral abstract

    Associations of Medical and Nonmedical Prescription Medication Use with Premature All-Cause Mortality Among US Adolescents

    Vita McCabe

    Examines how medical and nonmedical prescription medication use relates to early death among US adolescents.

    Child & Adolescent

  • 15:30–17:00 · Oral abstract

    Differential Retention by Substance Use Disorder Subtype in a Low-Barrier Walk-In Clinic: A Retrospective Cohort Study in Western Michigan

    Colleen Lane

    Retrospective study of treatment retention by substance use disorder type in a low-barrier walk-in clinic.

  • 15:30–17:00 · Oral abstract

    Factors Associated with Detoxification Completion in an Urban Substance Use Treatment Unit

    Kathryn Stevens

    Identifies factors linked to completing detoxification in an urban treatment unit.

Saturday, November 14

Sunday, November 15

Posters (57)

  • Addictions Psychiatry Didactic & Simulation: A Best Practice Teaching Pilot — Marc Hem Lee
  • Age-Specific Substance Use Trends in the United States, 2015-2024: Is the Greatest Burden Still among Younger Adults? — Dania Mofleh
  • Alterations in Muscarinic Acetylcholine Type-1 Receptors in People with Cocaine Use Disorder — Alejandra Pulido Saavedra
  • Cannabis Withdrawal Symptoms Can Occur Rapidly, be Severe and Bothersome, and Lead to Relapse in Daily/Near Daily Cannabis Users: Results of a Quantitative Cannabis User Survey — Shelli Graham
  • Changes in Knowledge, Attitudes, and Perceptions about Substance Use among Early Middle School Students after Introduction of Substance Use Prevention Curriculum: A Pilot Study — Meredith Nastruz
  • Associations between Cumulative Adversity and Quality of Life: The Roles of Substance Use and Post-Traumatic Stress among People Experiencing Homelessness — Ethan Faries
  • Characterizing Causal Genetic Relationships among Substance Use, Psychiatric, and Physical Health Disorders — Yousef Khan
  • Behind the Screen: How Social Media Can Help Treat Adolescent Substance Use Disorders — Pantea Farahmand
  • Enhancing Psychiatry Resident Readiness for Management of Addiction Consults on Call — Alexandra Schulz
  • Convergence of Suicide Attempts, Nonsuicidal Self-Injury, and Substance Use in Adolescents: A Retrospective Study of an Outpatient Substance Use Treatment Population — Muhammet Celik
  • Extreme Sports and Its Association with Substance use: A Scoping Review — Matin Narimani
  • Importance of Aggressive Early Treatment of Medetomidine Withdrawal — Kiana Malta
  • Cracking the Black Box of the Illicit Drug Supply: Clinically Relevant Insights from Drug Checking Data in San Diego — Joseph Friedma
  • Improving Identification and Treatment of Substance Use Disorders in Inpatient Psychiatry — Sean Woytowitz
  • Filling the gap in the adolescent substance use care continuum with thoughtful conversations — Linda DeMasi
  • Improving Understanding and Reducing Barriers to Utilizing Varenicline for Smoking Cessation Treatment through Accessible Infographic — Huailin Zhang
  • From Opioid Avoidance to Kratom Dependence: Treatment of Kratom Use Disorder with Long-Acting Injectable Buprenorphine — Alejandro Lopez
  • Hallucinogen Persisting Perception Disorder In An Adolescent: A Case Report — Phil Dohn
  • Hidden in Plain Sight: Cocaine Induced Midline Destructive Lesions Misdiagnosed as Granulomatosis with Polyangiitis in a High Functioning Patient with 40 Years of Concealed Cocaine Use — Angelica DiLorenzo
  • Integrating Evidence-Based Co-Occurring Disorder Treatment and Wraparound Support in a Massachusetts Adult Treatment Court — Hanaan Osman
  • Mechanisms and Durability of Residential Treatment for Co-Occurring Gambling and Substance Use Disorders: A Mixed-Methods Eight-Year Follow-Up Study — Jonah Im
  • Intravenous Use of Bupropion as a Cocaine Substitute: Examining its Acute Clinical Effects in a Psychiatric Crisis Center — Dennis Grapsas
  • Person-First Language in Statues for Commitment for Involuntary Substance Use Disorder Treatment — Oliver Fox
  • Medetomidine? What Happened to Xylazine?!?! A Case Example from Philadelphia and Literature Review — Paul Grey
  • Is There a Relationship between Rising ADHD Diagnoses and Methamphetamine Use Patterns? — Rachel Aniston
  • Kratom and 7OH: The 5th Wave of the Opioid Crisis — Arthur Robin Williams
  • Predictors of Readmission Following Inpatient Detoxification and Rehabilitation: The Role of Prior Treatment Utilization — William Fletes
  • Moderated and Unmoderated Digital Recovery Communities for Substance Use Disorders: A Systematic Review — Rameshwari Prasad
  • The Hottest Topic of Our Time: A Literature Review and Call to Action on Rising Heat and Substance Use Disorders — Alexa Hooberman
  • Short-Term Use of Kratom Resulting in Severe Hyponatremia: A Case Report. — Neha Agrawal
  • Recent Cocaine Use as a Predictor of 12-Month Treatment Engagement among Women Receiving Methadone Maintenance Treatment — Shai Smith
  • Single and multiple tobacco product use among people with mental illness and substance use disorders: Findings from the National Surveys on Drug Use and Health, 2022-2024 — Kelly Peck
  • Single-Dose 7-Hydroxymitragynine Induced Psychosis and Delirium Requiring Intensive Care — Jovesh Zachariah
  • Recovery Capital Better Predicts Favorable Discharge Than Psychiatric Symptom Severity in Residential SUD Treatment — Charles Rabinovich
  • From Association to Function: Neuronal Knockdown of GWAS Candidate Genes Alters Methamphetamine Response in Drosophila — Mert Karatas
  • Understanding the Trends in the National Survey on Gambling Attitudes and Gambling Experiences (NGAGE) across the Three Versions of the Survey — Tyler Kung
  • Substance Use Burden and Psychiatric Readmission following Long-Acting Injectable Antipsychotic Initiation — Angelo Chaia
  • Unsupervised Anabolic Steroid Use in a Patient on Methadone Maintenance Therapy: A Case Report Highlighting Gaps in Care Coordination and the Role of Addiction Psychiatry — William Jangro
  • Substance Use Patterns and Clinical Complexity as Predictors of Psychiatric Readmission among Inpatients Receiving Long-Acting Injectable Antipsychotics — Kathryn Renard
  • Resident-as-Teacher on the Addiction Psychiatry Consult-Liaison Service — Brittany Bamberg
  • Substance Use Treatment Characteristics and Outcomes in U.S. General Psychiatry Residency Programs, 2015-2025 — Sidarth Wakhlu
  • Reversible Cardiogenic Shock and Multiorgan Dysfunction Following 7-Hydroxymitragynine Overdose in an Adolescent: A Case Report — Alec Pupo
  • Successful Treatment of a Patient with Severe 7-OH Abuse and Chronic Psychosis. — Jenna Dolan
  • Severe Gambling Disorder Precipitated by Compounded Cyp Inhibition from Kratom and an Ssri in a Patient on Low-Dose Aripiprazole: A Novel Three-Way Pharmacokinetic Interaction — Zakariya Irfanullah
  • What is SR-17018? A Literature Review and Social Media Analysis of Real-World Use — Sarah Cheema
  • Sex Differences in Pain Relief as the Primary Motivation for Prescription Pain Reliever Misuse among U.S. Adults, 2015-2024 — Soohyun Joe
  • The Effects of Neuromodulation of craving, abstinence, mood, and Neurobiological Outcomes in Cocaine Use disorder: A Meta-Analytic Review — Manvir Bhangu
  • When Muscle Relaxation Unravels: A Case of Tizanidine Withdrawal — Claudia Cruz
  • When Psychiatry Changes the Stroke Workup: Nitrous Oxide Associated Mixed Arterial and Venous Thrombosis Presenting as Recurrent Stroke and Central Auditory Dysfunction — Mashal Jamil
  • Beyond the Biomarker: Structural and Linguistic Equity in Fitness-To-Drive Medical Assessment via Dichotomous Questionnaires — Cristian Palmiere
  • Comparative Analysis of State Policy Responses to Emerging Adulterants Xylazine and Medetomidine — Blessed Sheriff
  • Ocular Complications, Withdrawal, and Successful Naltrexone Treatment in Kratom Use Disorder: A Case Report — Yazmine Krentsa
  • Life-Threatening Cardiotoxicity from Chronic High-Dose Loperamide Misuse: A Case Report — Gulcan Yildiz
  • 7-Hydroxymitragynine Dependence with Severe Functional Impairment: Rapid Stabilization on Buprenorphine/Naloxone — Jason Della Vecchia
  • Online Sports Betting and Gambling Risk in Brazil: Nationally Representative Findings and Implications for Addiction Psychiatry — Daniel Heringer
  • I Heard My Story: A Qualitative Study of Recovery Experiences in Crystal Meth Anonymous — Julia Steigerwald Schnall
  • Acute Psychosis and Opioid Withdrawal Associated with 7-Hydroxymitragynine Use: A Case Report — Nicole Lord

Schedule to be announced

Other topics at this meeting

Opioid Use Disorder 48Cannabis & Cannabinoids 17Alcohol Use Disorder 16Child & Adolescent 14Drug Interactions & Safety 13Education & Training 12Schizophrenia & Psychosis 12Emergency & Acute Psychiatry 11Digital Psychiatry & AI 8Practice, Policy & Workforce 8PTSD & Trauma 8Long-Acting Injectables 7

Full program overview →